Study of a new drug for advanced stomach, esophagus, or pancreas cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new medication that targets a specific protein (CLDN18.2) found on some cancer cells. It may help people with advanced or metastatic stomach, esophageal, or pancreatic cancer who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic cancer of the stomach, esophagus, or pancreas (specifically adenocarcinoma).
- Your tumor shows a specific marker called CLDN18.2 (a protein on cancer cells).
- You have at least one tumor that can be measured on a scan.
- You are generally able to care for yourself (ECOG performance status 0 or 1).
- You have had at least one prior treatment for your advanced cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
This trial is testing a new combination of drugs (osemitamab, pembrolizumab, and chemotherapy) as the first treatment for advanced stomach cancer. It's for people whose tumors have a specific marker called Claudin 18.2, which might make the treatment more effective.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
This study tests a new experimental drug (AZD8359) designed to target prostate cancer cells in men whose cancer has progressed despite previous treatments. The drug works by directing immune cells to attack cancer cells.
This trial tests a new drug called CT0494BCP for advanced stomach cancer that has not responded to previous treatments. The drug targets a protein called CLDN18.2, which is found on many stomach cancer cells, and aims to help your immune system fight the cancer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.